Search for content, post, videos

Ardelyx, AZ to Review Agreement

agreement
Shares of Ardelyx dropped in after-market trading earlier this week after the AstraZeneca partner acknowledged that its lead drug tenapanor was unimpressive in a Phase IIa study. Ardelyx, based in California, says that tenapanor missed the primary endpoint among 154 patients with Stage 3 chronic
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.